Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Fred Saad, MD, discusses results...